When did ANEBULO PHARMACEUTICALS INC (ANEB) report earnings last quarter?
ANEBULO PHARMACEUTICALS INC (ANEB) last reported earnings on 2/12/2026.
NASDAQ:ANEB • US0345691036
Past quarterly earnings results for ANEBULO PHARMACEUTICALS INC (ANEB), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | -0.05 | -0.13 | 62.29% | 44.44% | - | - | ||
| Q1 2026 | -0.05 | -0.12 | 59.15% | 37.50% | - | - | ||
| Q4 2025 | -0.05 | -0.08 | 38.73% | - | - | - | ||
| Q3 2025 | -0.04 | -0.05 | 21.57% | 33.33% | - | - | ||
| Q2 2025 | -0.09 | -0.08 | -10.29% | 18.18% | - | - | ||
| Q1 2025 | -0.08 | -0.05 | -56.86% | 20.00% | - | - | ||
| Q4 2024 | -0.05 | -0.13 | 62.44% | 50.00% | - | - | ||
| Q3 2024 | -0.06 | -0.12 | 50.15% | 45.45% | - | - | ||
| Q2 2024 | -0.11 | -0.10 | -7.84% | 26.67% | - | - | ||
| Q1 2024 | -0.10 | -0.12 | 15.97% | 9.09% | - | - | ||
| Q4 2023 | -0.10 | -0.11 | 11.41% | - | - | - | ||
| Q3 2023 | -0.11 | -0.16 | 31.31% | -37.50% | - | - | ||
| Q2 2023 | -0.15 | -0.11 | -33.69% | -200.00% | - | - | ||
| Q1 2023 | -0.11 | -0.11 | -2.71% | - | - | - | ||
| Q4 2022 | -0.10 | -0.08 | -30.72% | 28.57% | - | - | ||
| Q3 2022 | -0.08 | -0.05 | -56.86% | 88.41% | - | - | ||
| Q2 2022 | -0.05 | -0.06 | 18.30% | - | - | - | ||
| Q1 2022 | - | - | - | - | ||||
| Q4 2021 | -0.14 | -0.03 | -357.52% | - | - | - | ||
| Q3 2021 | -0.69 | -0.07 | -866.39% | - | - | - | ||
| Q2 2021 | - | - | - | - | ||||
| Q1 2021 | -0.69 | -0.04 | -1,591.18% | - | - | - |
Notes
ANEBULO PHARMACEUTICALS INC (ANEB) last reported earnings on 2/12/2026.
ANEBULO PHARMACEUTICALS INC (ANEB) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, ANEBULO PHARMACEUTICALS INC (ANEB) has beaten EPS estimates in 4 out of 4 releases.